BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Belén LH, Lissabet JB, de Oliveira Rangel-yagui C, Effer B, Monteiro G, Pessoa A, Farías Avendaño JG. A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora. Biologicals 2019;59:47-55. [DOI: 10.1016/j.biologicals.2019.03.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Yang W, Smith CA, Cheng C, Karol SE, Larsen EC, Winick N, Carroll WL, Loh ML, Raetz EA, Hunger SP, Winter SS, Dunsmore KP, Devidas M, Yang JJ, Evans WE, Jeha S, Pui C, Inaba H, Relling MV. Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. Clin Pharmacol Ther 2021;110:794-802. [DOI: 10.1002/cpt.2241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ameen F, Alshehri WA, Al-enazi NM, Almansob A. L-Asparaginase activity analysis, ansZ gene identification and anticancer activity of a new Bacillus subtilis isolated from sponges of the Red Sea. Bioscience, Biotechnology, and Biochemistry 2020;84:2576-84. [DOI: 10.1080/09168451.2020.1807310] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
3 Beckett A, Gervais D. What makes a good new therapeutic l-asparaginase? World J Microbiol Biotechnol 2019;35. [DOI: 10.1007/s11274-019-2731-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
4 Lima Parente Fernandes M, Alcântara Veríssimo LA, Cristina de Souza A, Schwan RF, Ribeiro Dias D. Low-cost agro-industrial sources as a substrate for the production of l-asparaginase using filamentous fungi. Biocatalysis and Agricultural Biotechnology 2021;34:102037. [DOI: 10.1016/j.bcab.2021.102037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fonseca MHG, Fiúza TDS, Morais SB, Souza TACB, Trevizani R. Circumventing the side effects of L-asparaginase. Biomed Pharmacother 2021;139:111616. [PMID: 33932739 DOI: 10.1016/j.biopha.2021.111616] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Śliwa-tytko P, Kaczmarska A, Lejman M, Zawitkowska J. Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy. IJMS 2022;23:5515. [DOI: 10.3390/ijms23105515] [Reference Citation Analysis]
7 Costa-silva T, Costa I, Biasoto H, Lima G, Silva C, Pessoa A, Monteiro G. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer. Blood Reviews 2020;43:100651. [DOI: 10.1016/j.blre.2020.100651] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
8 Maggi M, Pessino G, Guardamagna I, Lonati L, Pulimeno C, Scotti C. A Targeted Catalytic Nanobody (T-CAN) with Asparaginolytic Activity. Cancers (Basel) 2021;13:5637. [PMID: 34830793 DOI: 10.3390/cancers13225637] [Reference Citation Analysis]
9 Masri M, Nur F, Widodo J, Jusuf E, Sahar W, Wahida N, Risnawati R, Nurbaya S, Asri TA, Fadly N. A novel L‐asparaginase from the symbiotic Enterobacter aerogenes isolated from Eucheuma sp. Food Processing Preservation. [DOI: 10.1111/jfpp.16306] [Reference Citation Analysis]